NexImmune is an emerging biopharmaceutical company advancing a new generation of immunotherapies based on our proprietary AIM™ technology. This nanotechnology platform, originally developed at Johns Hopkins University, is the foundation for an innovative approach to immunotherapy in which the body’s own immune system is stimulated to orchestrate a targeted T cell response against a disease. Central to the AIM technology are artificial Antigen Presenting Cells (aAPC) that present antigens to T cells eliciting a highly targeted therapy driven by the patient’s immune system. These aAPC can be rapidly engineered to elicit a specific immune attack that can be directed toward any foreign substance or cell type in a patient’s body.
Our first product, for the treatment of cancer, is expected to enter clinical trials in 2018.
An innovative approach to immunotherapy in which immune system is guided by a synthetic aAPC that has been engineered to orchestrate a targeted T cell response.Learn More
Our first two products use aAPC to stimulate multiple antigen-specific, cancer-fighting T cells for the treatment of cancer.
Our first products use aAPC to stimulate multiple antigen-specific, cancer-fighting T cells for the treatment of cancer.